Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG

Telix is pleased to announce that it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG for the supply of highly pure no-carrier-added (n.c.a) lutetium-177 (177Lu), a therapeutic isotope used in Telix’s portfolio of Molecularly Targeted Radiation (MTR) products.

Telix CEO Christian Behrenbruch stated, “ITM is a leading global supplier of high quality medical radioisotopes, and has established significant production capacity for n.c.a lutetium, a radioisotope that has potentially broad applications in the treatment of human cancers. These agreements with ITM will support both near-term clinical trial activity and commercial-scale activity in the future.”

ITM CEO Steffen Schuster added, “Through these global supply agreements with Telix, we have further expanded our international leadership position as a premier developer and supplier of radioisotopes. Telix shares our vision of leveraging the full potential of nuclear medicine for the benefit of patients and we look forward to continuing our strong global collaboration with them.” 

Under the terms of the revised agreements, ITM will supply 177Lu for use in Telix’s investigational programs in prostate and renal cancer therapy.

To read the full ASX release, click here.

To visit Telix’s website, click here.

Register Interest

About Telix Pharmaceuticals Limited (ASX: TLX)

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix’s products address significant unmet medical needs in prostate, kidney, glioblastoma (brain) and hematologic (blood) cancers, as well as a range of immunologic and high value rare diseases.

The Company is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States, and is listed on the Australian Securities Exchange (ASX: TLX).

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and has been granted Priority Review status by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix® in the European Union and Canada. None of Telix’s products have currently received a marketing authorisation in any jurisdiction. For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Register Interest